FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.

Wendy Crouse, DVM, an independent house call veterinarian with Heal House Call Veterinarian, sat down with Drug Topics to discuss how the adoption of e-prescribing has transformed her practice.

With more states allowing the use of recreational marijuana than ever before, researchers examined its effects among youth populations.

Kevin Hope, RPh, senior director of pharmacy education at Pharmcon, joined Drug Topics to discuss pharmacy compounding from the new USP changes and the importance of education around compounding best practices.

By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.